Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Blocking endogenous IL-6 impairs mobilization of free fatty acids during rest and exercise in lean and obese men

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Altered brown fat thermoregulation and enhanced cold-induced thermogenesis in young, healthy, winter-swimming men

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Altered brown fat thermoregulation and enhanced cold-induced thermogenesis in young, healthy, winter-swimming men

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Neprilysin inhibition increases glucagon levels in humans and mice with potential effects on amino acid metabolism

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The regulation of circulating hepatokines by fructose ingestion in humans

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Lack of interleukin-6 (IL-6) leads to expansion of adipose tissue mass in rodents and humans. The exact underlying mechanisms have not been identified. In this placebo-controlled, non-randomized, participant-blinded crossover study, we use the IL-6 receptor antibody tocilizumab to investigate the role of endogenous IL-6 in regulating systemic energy metabolism at rest and during exercise and recovery in lean and obese men using tracer dilution methodology. Tocilizumab reduces fatty acid appearance in the circulation under all conditions in lean and obese individuals, whereas lipolysis (the rate of glycerol appearance into the circulation) is mostly unaffected. The fact that fatty acid oxidation is unaffected by IL-6 receptor blockade suggests increased re-esterification of fatty acids. Glucose kinetics are unaffected. We find that blocking endogenous IL-6 signaling with tocilizumab impairs fat mobilization, which may contribute to expansion of adipose tissue mass and, thus, affect the health of individuals undergoing anti-IL-6 therapy (Clinicaltrials.gov: NCT03967691).

Original languageEnglish
Article number100396
JournalCell reports. Medicine
Volume2
Issue number9
Pages (from-to)100396
ISSN2666-3791
DOIs
Publication statusPublished - 21 Sep 2021

Bibliographical note

© 2021 The Authors.

ID: 68349002